Transplantation Guidelines

Transplant Patients for Registration with UKT for Solid Organ Transplantation

HLA (Human Leucocyte Antigens) are expressed on the surface of cells and involved in the recognition of self and non-self. They are used in matching donor/recipient pairs in accordance with the national allocation scheme. 

Potential kidney transplant recipients will be typed for HLA Class I and II antigens (HLA A, B, Cw, DR, DQ), blood grouped and screened for lymphocytotoxic antibodies. Once tests have been performed the laboratory will complete the appropriate sections of the UKT registration form and forward this to the recipient's centre for completion and submission.  

Bone Marrow Transplant Patients/Donors 

Close matches at the DNA level are required for BMT to minimise the chances of GvHD.

Patients are typed for Class I and II antigens using molecular techniques (HLA A, B, Cw, DR, DQ), blood grouped and screened for lymphocytotoxic antibodies.

Family donors are Class I typed and if matched Class II typed and blood grouped.

Matched Unrelated Donors (MUD) searches are only performed at the request of the Consultant. 

Lymphocytotoxic Antibody Screening 

Patients can form HLA antibodies following transfusion, transplantation and pregnancy. It is essential that patients on the UKT kidney/pancreas waiting list are monitored every three months or following a sensitising event. All changes to the patients sensitisation status are reported to UKT by the laboratory. 

Crossmatching

Performed prior to transplantation to exclude donors expressing antigens to which the patient has preformed antibodies thus minimising the risk of hyperacute rejection.  

Disease and Drug Hypersensitivity Associations

Certain diseases/hypersensitivity conditions have been shown to have positive or negative association with certain HLA antigens/alleles (quantified as 'relative risk'). Reported as positive or negative for the associated antigen/allele  

Immunosuppressive Drug Monitoring

Performed as an aid to dosage adjustment in patients receiving immunosuppressive therapy following transplantation or in the treatment of autoimmune disease. 


Page updated: 11/01/11 | Updated by: Webmaster

Transplantation Guidelines Links